In vivo, tumorigenic assays showed that HDAC2 downregulation and Bcl2 inhibited tumorigenic activity and enhanced apoptosis in glioma cells, while DNMT3B promoted tumorigenic activity and inhibited apoptosis in tissues. This evidence concerns the gene DNMT3B and central nervous system cancer.